TAXANES IN THE TREATMENT OF BREAST AND OVARIAN CANCERS - CURRENT INDICATIONS AND RESULTS

Since the last years, taxanes are among the most active molecules in t he treatment of advanced breast and ovarian cancers. Concerning the ov arian cancer, Paclitaxel in association with Cisplatinum is about to b ecome the first line reference protocol. Studies are going on in order to define the association and the optimal way of administration. Conc erning breast cancer, Docetaxel seems to provide the most interesting response rates after failures of anthracyclines. In France, randomised studies in adjuvant situation have started with this molecule.